Cost-effectiveness analysis of newborn screening for sickle-cell disease in Spain.

Castilla-Rodriguez I, Cela E, Vallejo-Torres L, Valcarcel-Nazco C, Dulin E, Espada M, Rausell D, Mar J, Serrano-Aguilar P.

Expert Opinion On Orphan Drugs. 2016; 4: 567-575. FI: 0,559 (Q4).

Advanced prostate cancer survival in Spain according to the Gleason score, age and stage.

Campá J, Mar-Barrutia G, Extramiana J, Arróspide A, Mar J.

Actas Urologicas Espanolas. 2016; 40: 499-506. FI: 1,181 (Q4).

Validation and comparison of instruments to identify frail patientes in primary care settings: Study protocol.

Vergara I, Rivas-Ruiz F, Vrotsou K, Contreras-Fernández E, Téllez-Santana T, Machón M, Díez Ruiz AI, de Mesa Berenguer Y, Bueno A, Núñez J, Saucedo Figueredo MC, Montiel-Luque A, Nava Del Val MA, Quirós-López R, Carrasco E, Abellan G.

Bmc Health Services Research. 2016; 16: 354-354. FI: 1,827 (Q3).

Minimum intravenous thrombolysis utilization rates in acute ischemic stroke to achieve population effects on disability: A discrete-event simulation model.

Hoffmeister L, Lavados PM, Mar J, Comas M, Arrospide A, Castells X.

Journal Of The Neurological Sciences. 2016; 365: 59-64. FI: 2,295 (Q3).

Proposal to inform European institutions regarding the regulation of conscientious objection to abortion.

Lertxundi R, Ibarrondo O, Merki-Feld GS, Rey-Novoa M, Rowlands S, Mar J.

European Journal Of Contraception And Reproductive Health Care. 2016; 21: 198-200. FI: 1,627 (Q3).

Análisis coste-efectividad del tratamiento de la hepatitis C crónica con sofosbuvir-simeprevir en pacientes con genotipo 1 y fibrosis avanzada.

Mar J, Mar-Barrutia L, Gimeno-Ballester V, San Miguel R.

Medicina Clinica. 2016; 146: 61-64. FI: 1,125 (Q3).

[Prevalence of altered mismatch repair protein nuclear expression detected by immunohistochemistry on adenomas with high-grade dysplasia and features associated with this risk in a population-based study].

Basterra M, Gomez M, Mercado Mdel R, Irisarri R, Amorena E, Arrospide A, Montes M, Aisa G, Cambra KI, Urman J.

Gastroenterologia Y Hepatologia. 2016; 39: 500-507. FI: 0,917 (Q4).

Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.

Gimeno-Ballester V, Simón MA, Trigo C, Mar J, San Miguel R.

Expert Rev Gastroent. 2016; 10: 1289-1303. FI: 2,743 (Q3).

Development and Validation of the COMPLES Score for Differentiating Between Tuberculous Effusions with Low Pleural pH or Glucose and Complicated Parapneumonic Effusions.

Corral-Gudino L, García-Zamalloa A, Prada-González C, Bielsa S, Alexis D, Taboada-Gómez J, Dos-Santos-Gallego PR, Alonso-Fernández MA, Porcel JM.

Lung. 2016; 194: 847-854. FI: 1,915 (Q3).

La formación entre iguales para pacientes con diabetes mellitus 2. Una evaluación cuantitativa y cualitativa en el País Vasco y Andalucía.

Danet A, Prieto Rodríguez MA, Gamboa Moreno E, Ochoa de Retana Garcia L, March Cerdà JC.

Atencion Primaria. 2016; 48: 507-517. FI: 1,042 (Q3).